Inhaled budesonide does not prevent acute mountain sickness after rapid ascent to 4559 m

Eur Respir J. 2017 Sep 10;50(3):1700982. doi: 10.1183/13993003.00982-2017. Print 2017 Sep.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Altitude
  • Altitude Sickness / etiology
  • Altitude Sickness / prevention & control*
  • Austria
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / adverse effects
  • Budesonide* / administration & dosage
  • Budesonide* / adverse effects
  • Female
  • Humans
  • Male
  • Mountaineering / physiology*
  • Respiratory Therapy / methods
  • Treatment Failure

Substances

  • Bronchodilator Agents
  • Budesonide

Associated data

  • ClinicalTrials.gov/NCT02811016